CN103405447A - Application of Chukrasone A in medicaments for treating nasopharyngeal carcinoma - Google Patents
Application of Chukrasone A in medicaments for treating nasopharyngeal carcinoma Download PDFInfo
- Publication number
- CN103405447A CN103405447A CN2013103841659A CN201310384165A CN103405447A CN 103405447 A CN103405447 A CN 103405447A CN 2013103841659 A CN2013103841659 A CN 2013103841659A CN 201310384165 A CN201310384165 A CN 201310384165A CN 103405447 A CN103405447 A CN 103405447A
- Authority
- CN
- China
- Prior art keywords
- chukrasone
- nasopharyngeal carcinoma
- application
- medicaments
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HZUBWSRMDOJYPS-WPCVKUBSSA-N chukrasone A Natural products C=1([C@@H]2OC(=O)C[C@H]3[C@@]4(O)[C@H](O)C(=O)[C@@]5(O)[C@@H](OC(=O)C(C)C)C(C)(C)[C@@H]([C@]5([C@H]4[C@H](OC(C)=O)C[C@]32C)C)CC(=O)OC)C=COC=1 HZUBWSRMDOJYPS-WPCVKUBSSA-N 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 title abstract description 17
- 206010061306 Nasopharyngeal cancer Diseases 0.000 title abstract description 17
- 201000011216 nasopharynx carcinoma Diseases 0.000 title abstract description 17
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 7
- 230000012010 growth Effects 0.000 abstract description 7
- 101150080924 CNE1 gene Proteins 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 abstract 1
- 238000002841 anti-cancer assay Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 241001156380 Chukrasia tabularis Species 0.000 description 2
- 108010087141 Kv1.2 Potassium Channel Proteins 0.000 description 2
- 102000006628 Kv1.2 Potassium Channel Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003450 potassium channel blocker Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310384165.9A CN103405447B (en) | 2013-08-29 | 2013-08-29 | The application of Chukrasone A in preparation treatment medicine for nasopharyngeal |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310384165.9A CN103405447B (en) | 2013-08-29 | 2013-08-29 | The application of Chukrasone A in preparation treatment medicine for nasopharyngeal |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103405447A true CN103405447A (en) | 2013-11-27 |
CN103405447B CN103405447B (en) | 2015-08-05 |
Family
ID=49598521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310384165.9A Expired - Fee Related CN103405447B (en) | 2013-08-29 | 2013-08-29 | The application of Chukrasone A in preparation treatment medicine for nasopharyngeal |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103405447B (en) |
-
2013
- 2013-08-29 CN CN201310384165.9A patent/CN103405447B/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
HONG-BING LIU ET AL: "《Chukrasones A and B: Potential Kv1.2Potassium Channel Blockers with NewSkeletons from Chukrasia tabularis》", 《ORGANIC LETTERS》, vol. 14, no. 17, 8 October 2012 (2012-10-08), pages 4438 - 41 * |
Also Published As
Publication number | Publication date |
---|---|
CN103405447B (en) | 2015-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103251609A (en) | Application of Aspeverin in preparation of medicines for treating tongue cancer | |
CN103405424A (en) | Application of Chukrasone B in medicine for treating colorectal cancer | |
CN103405418A (en) | Application of Chukrasone B in medicine for treating breast cancer | |
CN102885844B (en) | Application of Houttuynoid B in medicine for treating tongue cancer | |
CN102861080B (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
CN103405447A (en) | Application of Chukrasone A in medicaments for treating nasopharyngeal carcinoma | |
CN103127091A (en) | Application of Aphanamixoid A in medicines curing colorectal cancer | |
CN103405455A (en) | Application of Chukrasone A in medicaments for treating laryngocarcinoma | |
CN103405420A (en) | Application of Chukrasone B in medicine for treating nasopharynx cancer | |
CN103405451A (en) | Application of Chukrasone A in medicaments for treating tongue carcinoma | |
CN103405450A (en) | Application of Chukrasone A in medicaments for treating cervical carcinoma | |
CN103405445A (en) | Application of Chukrasone A in medicaments for treating colorectal carcinoma | |
CN103405409A (en) | Application of Chukrasone B in medicine for treating ovarian cancer | |
CN103405457A (en) | Application of Chukrasone A in medicaments for treating skin carcinoma | |
CN103405453A (en) | Application of Chukrasone A in medicaments for treating pancreatic carcinoma | |
CN103405454A (en) | Application of Chukrasone A in medicaments for treating renal carcinoma | |
CN103405449A (en) | Application of Chukrasone A in medicaments for treating breast carcinoma | |
CN103405444A (en) | Application of Chukrasone A in medicaments for treating bladder cancer | |
CN103405413A (en) | Application of Chukrasone B in medicaments for treating bladder cancer | |
CN103405459A (en) | Application of Chukrasone A in medicaments for treating prostatic carcinoma | |
CN103405452A (en) | Application of Chukrasone A in medicaments for treating gastric carcinoma | |
CN103405421A (en) | Application of Chukrasone B in medicine for treating cervical cancer | |
CN103356571A (en) | Application of Sarcaboside B in preparation of medicines for treating nasopharynx cancer | |
CN103405416A (en) | Application of Chukrasone B in medicine for treating endometrial cancer | |
CN103405446A (en) | Application of Chukrasone A in medicaments for treating bile duct carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Wu Junhua Inventor after: Luo Dongjun Inventor after: Huang Rong Inventor after: Wang Hui Inventor after: Wu Junyi Inventor after: Zhang Guang Inventor after: Jiang Chunping Inventor before: Huang Rong Inventor before: Wang Hui Inventor before: Wu Junyi Inventor before: Zhang Guang Inventor before: Jiang Chunping Inventor before: Wu Junhua |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: HUANG RONG WANG HUI WU JUNYI ZHANG GUANG JIANG CHUNPING WU JUNHUA TO: WU JUNHUA LUO DONGJUN HUANG RONG WANG HUI WU JUNYI ZHANG GUANG JIANG CHUNPING |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150805 Termination date: 20160829 |